Combined effects of C225 and 125-iodine seed radiation on colorectal cancer cells

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Liu, Jingjia ^a   Wang, Hao ^a   Qu, Ang ^a   Li, Jinna ^a   Zhao, Yong ^b   Wang, Junjie ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b INSTITUTE OF ZOOLOGY   (China)

Author keywords

H2AX; Apoptosis; C225; DNA repair; DNA PK

Indexed keywords

CELL DNA; CETUXIMAB; IODINE 125; PROTEIN BAX; PROTEIN KINASE B; RADIOACTIVE SEED; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; RADIOSENSITIZING AGENT;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; RADIATION DOSE; RADIOSENSITIVITY; SENSITIZATION; WESTERN BLOTTING; BRACHYTHERAPY; COLORECTAL TUMOR; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BLOTTING, WESTERN; BRACHYTHERAPY; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA REPAIR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IODINE RADIOISOTOPES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84884384892     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-219     Document Type: Article

References (24)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150. 10.1200/JCO.2005.05.2308, 16682732.
2. Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 2010, 5:88. 10.1186/1748-717X-5-88, 2955594, 20920276.
3. Smith JA, Wild AT, Singhi A, et al. Clinicopathologic comparison of high-dose-rate endorectal brachytherapy versus conventional chemoradiotherapy in the neoadjuvant setting for resectable stages II and III Low rectal cancer. Int J Surg Oncol 2012, 2012:406568. 3399366, 22830003.
4. Vuong T, Devic S, Podgorsak E. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin Oncol (R Coll Radiol) 2007, 19(9):701-705.
5. Sun Myint A, Mukhopadhyay T, Ramani VS, et al. Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes?. Colorectal Dis 2010, 12(Suppl 2):30-36.
6. Wang JJ, Yuan HS, Li JN, et al. Interstitial permanent implantation of I-125 seeds as salvage therapy for re-recurrent rectal carcinoma. Int J Colorectal Dis 2009, 24(4):391-399. 10.1007/s00384-008-0628-4, 19084969.
7. Meyn RE, Munshi A, Haymach JV, et al. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol 2009, 92(3):316-322. 10.1016/j.radonc.2009.06.031, 2754282, 19615770.
8. Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007, 13(22 Pt 1):6555-6560.
9. Nyati MK, Morgan MA, Feng FY, et al. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006, 6(11):876-885. 10.1038/nrc1953, 17036041.
10. Dale RG, Jones B. The clinical radiobiology of brachytherapy. Br J Radiol 1998, 71(845):465-483.
11. Kolotas C, Roddiger S, Strassmann G, et al. Palliative interstitial HDR brachytherapy for recurrent rectal cancer, implantation techniques and results. Strahlenther Onkol 2003, 179(7):458-463.
12. Liang K, Ang KK, Milas L, et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003, 57(1):246-254. 10.1016/S0360-3016(03)00511-X, 12909240.
13. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578. 10.1056/NEJMoa053422, 16467544.
14. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59(8):1935-1940.
15. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008, 18(1):134-147. 10.1038/cr.2007.111, 18157161.
16. Mao Z, Bozzella M, Seluanov A, et al. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst) 2008, 7(10):1765-1771.
17. Sedelnikova OA, Pilch DR, Redon C, et al. Histone H2AX in DNA damage and repair. Cancer Biol Ther 2003, 2(3):233-235.
18. Takahashi A, Ohnishi T. Does gammaH2AX foci formation depend on the presence of DNA double strand breaks?. Cancer Lett 2005, 229(2):171-179. 10.1016/j.canlet.2005.07.016, 16129552.
19. Banath JP, Klokov D, MacPhail SH, et al. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer 2010, 10:4. 10.1186/1471-2407-10-4, 2819996, 20051134.
20. Choi EJ, Ryu YK, Kim SY, et al. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res 2010, 8(7):1027-1036. 10.1158/1541-7786.MCR-09-0507, 20587532.
21. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002, 8(3):885-892.
22. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 2009, 19(1):63-68. 10.1016/j.semradonc.2008.09.009, 3216119, 19028347.
23. Zhuang HQ, Wang JJ, Liao AY, et al. The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res 2009, 28:12. 10.1186/1756-9966-28-12, 2655271, 19175942.
24. Wang J, Wang J, Liao A, et al. The direct biologic effects of radioactive 125I seeds on pancreatic cancer cells PANC-1, at continuous low-dose rates. Cancer Biother Radiopharm 2009, 24(4):409-416. 10.1089/cbr.2008.0563, 19694575.